MediWound Ltd.
- Open
- 13.10
- Day high
- 13.33
- Day low
- 12.79
- Prev close
- 13.06
- Volume
- 72K
- Mkt cap
- $171M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.8
- P/S
- 14.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$49K over the last 3 months (1 open-market buy, 3 sales)
- 🏛Institutions accumulating (13F)
MediWound Ltd. (MDWD) is a Healthcare company listed on NASDAQ. The stock is down 21% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 3 sales (SEC Form 4). Drillr has 1 published research article covering MDWD.
MediWound Ltd. (MDWD) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
MDWD earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.76 | $-0.77 | -1.1% | $3M | +15.6% |
| May 27, 2026 | $-0.65 | $-0.23 | +64.6% | $1M | -56.2% |
| Mar 5, 2026 | $-0.65 | $-0.56 | +13.8% | $2M | -61.5% |
| Nov 20, 2025 | $-0.81 | $-0.24 | +70.4% | $5M | +147.0% |
| Aug 14, 2025 | $-0.55 | $-1.23 | -123.6% | $6M | -11.9% |
| May 21, 2025 | $-0.65 | $-0.07 | +89.2% | $4M | -31.1% |
| Mar 19, 2025 | $-0.59 | $-0.36 | +39.0% | $6M | +12.3% |
| Nov 26, 2024 | $-0.44 | $-0.98 | -122.7% | $4M | -23.9% |
| Aug 14, 2024 | $-0.42 | $-0.68 | -61.9% | $5M | -15.8% |
| May 29, 2024 | $-0.40 | $-0.39 | +2.5% | $5M | +6.3% |
| Mar 21, 2024 | $-0.23 | $-0.19 | +17.4% | $5M | +0.3% |
| Nov 21, 2023 | $-0.45 | $-0.24 | +46.7% | $5M | -5.6% |
MDWD insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Rubinstein Samueldirector | Sell | 525 | $12.72 |
| Sep 2, 2026 | Rubinstein Samueldirector | Buy | 525 | $12.62 |
| Aug 28, 2026 | Hess Shmuelofficer: COO & Chief Commercial Officer | Sell | 1,865 | $13.00 |
| Aug 28, 2026 | Hess Shmuelofficer: COO & Chief Commercial Officer | Sell | 1,979 | $12.72 |
| Aug 28, 2026 | Hess Shmuelofficer: COO & Chief Commercial Officer | Option | 5,000 | $8.13 |
| Aug 28, 2026 | Hess Shmuelofficer: COO & Chief Commercial Officer | Option | 11,000 | $8.13 |
| Jun 4, 2026 | SHAMIR NACHUMdirector | Buy | 175 | $13.97 |
| Jun 4, 2026 | SHAMIR NACHUMdirector | Buy | 5,825 | $14.00 |
| Jun 2, 2026 | Fox David Mortondirector | Buy | 1,730 | $14.22 |
| Jun 2, 2026 | Fox David Mortondirector | Buy | 10 | $14.23 |
| Jun 2, 2026 | Fox David Mortondirector | Buy | 1,797 | $13.99 |
| Jun 1, 2026 | Rubinstein Samueldirector | Buy | 150 | $14.33 |
Source: MDWD SEC Form 4 filings, latest Sep 2, 2026. For informational purposes only — not investment advice.
See the full MDWD insider & 13F page →MediWound Ltd. company profile
Overview
MediWound Ltd. (NASDAQ:MDWD) is an Israeli biopharmaceutical company founded in 2000 and headquartered in Yavne, Israel. The company went public on NASDAQ in March 2014. MediWound specializes in developing, manufacturing, and commercializing novel enzymatic bio-therapeutic solutions for tissue repair and regeneration, with a primary focus on wound debridement - the medical process of removing dead, damaged, or infected tissue to promote healing.
Business
MediWound operates in the specialized biotechnology sector focused on enzymatic debridement - a medical technique that uses naturally occurring enzymes to remove dead tissue from wounds. The company's core technology platform is based on proprietary enzyme formulations that can selectively target and dissolve necrotic (dead) tissue while preserving healthy tissue. The company's primary commercial product is NexoBrid, an enzymatic debridement agent specifically designed for treating severe thermal burns. NexoBrid contains a concentrate of proteolytic enzymes derived from bromelain (pineapple stem enzymes) that can remove eschar - the thick, leathery dead tissue that forms over deep burns. Traditional burn treatment requires surgical debridement, which involves physically cutting away dead tissue, often requiring multiple surgeries and potentially removing healthy tissue. NexoBrid offers a non-surgical alternative that can achieve complete debridement in a single 4-hour application. The company's pipeline includes EscharEx, which uses the same enzymatic platform but is formulated for chronic wounds such as venous leg ulcers and diabetic foot ulcers. These chronic wounds affect millions of patients worldwide and often fail to heal properly due to the presence of necrotic tissue that prevents new tissue growth. EscharEx is currently in Phase III clinical trials. Additionally, MediWound is developing MW005 for treating basal cell carcinoma, a common form of skin cancer, which is in Phase I/II trials. The company generates revenue primarily from NexoBrid sales, which represented approximately 100% of product revenue in 2024 at $20.2 million.
Revenue model
MediWound operates a product sales business model combined with strategic licensing partnerships. The company generates revenue through direct sales of NexoBrid to hospitals and burn centers, primarily in Europe where the product has been commercially available since 2012. In the United States, NexoBrid received FDA approval in December 2022 and is distributed through an exclusive partnership with Vericel Corporation, which provides MediWound with milestone payments and royalties on sales. The company's paying customers are primarily hospital burn units and specialized burn centers. NexoBrid is typically purchased by hospital pharmacy departments and used by burn surgeons and wound care specialists. The product commands premium pricing due to its unique mechanism of action and ability to reduce the need for surgical debridement procedures. Key factors that could increase margins include expanded manufacturing capacity (the company completed a new GMP facility in 2024 that will increase production six-fold), broader market penetration as more hospitals adopt the technology, and successful launch of EscharEx which targets a much larger chronic wound market estimated at over $2 billion globally. The company also benefits from limited competition, as enzymatic debridement is currently dominated by a single older product (collagenase) that generates approximately $300 million in annual sales. Factors that could pressure margins include manufacturing scale-up costs, extensive clinical trial expenses for pipeline products, regulatory compliance costs, and potential competition from new entrants. The company also faces reimbursement challenges in some markets, as healthcare systems may be slow to adopt new technologies despite their clinical benefits.
Competitive moat
MediWound possesses a moderate but defensible moat based on several factors. The company's primary competitive advantage lies in its proprietary enzymatic formulation and specialized manufacturing expertise. The bromelain-based enzyme concentrate requires specific processing and stabilization techniques that create technical barriers for potential competitors. The regulatory moat is significant, as achieving FDA and EMA approvals for enzymatic debridement products requires extensive clinical trials demonstrating both safety and efficacy. MediWound's established regulatory pathway and clinical data represent years of investment that competitors would need to replicate. The company also benefits from intellectual property protection through patents covering its formulations and manufacturing processes. However, the moat faces several challenges. The enzymatic debridement market is relatively small, limiting the economic incentive for large pharmaceutical companies to invest heavily in competing products. The existing competition from collagenase-based products (such as SANTYL) demonstrates that alternative enzymatic approaches are viable. Additionally, advances in surgical techniques, wound care technologies, or entirely different therapeutic approaches could potentially disrupt the enzymatic debridement market. The company's moat is strengthened by its expanding clinical evidence base and growing physician familiarity with enzymatic debridement. As more burn centers and wound care specialists gain experience with NexoBrid, switching costs increase due to training requirements and established protocols. The planned launch of EscharEx could significantly expand the moat by establishing MediWound as the leader in enzymatic debridement across multiple wound types.
Risks & safety
MediWound presents a moderate margin of safety with some financial concerns but reasonable liquidity position. • **Cash and Liquidity**: $9.2 million cash at end of 2024, down from $35.6 million in Q1 2024, indicating rapid cash burn • **Debt Level**: Low debt-to-equity ratio of 0.21, minimal solvency risk from leverage • **Cash Burn**: Significant negative free cash flow of -$19.9 million in 2024, with operating cash flow of -$13.6 million • **Current Ratio**: Healthy 1.97, indicating ability to meet short-term obligations • **Valuation Metrics**: Trading at 6.2x price-to-book ratio, negative EV/EBITDA due to losses • **Revenue Growth**: Positive revenue trajectory with NexoBrid sales growing and projected $24 million for 2025 • **Funding Needs**: Company will likely need additional financing within 12-18 months given current burn rate, though recent €16.5 million EU funding and $25 million PIPE financing provide some runway
Recent development
Over the past few years, MediWound has executed several key strategic initiatives to expand its commercial footprint and pipeline. The most significant milestone was achieving FDA approval for NexoBrid in December 2022, opening the large U.S. burn treatment market. The company has systematically expanded U.S. market penetration, with over 70 burn centers submitting applications to their pharmacy committees and more than 40 centers receiving approvals by 2024. The company completed construction of a state-of-the-art GMP manufacturing facility that will increase production capacity six-fold when fully operational in 2025-2026. This addresses the current supply constraint where demand exceeds production capacity by 2-3 times. MediWound also secured FDA approval for pediatric use of NexoBrid in Europe and is pursuing similar approval in the United States. For its pipeline, the company advanced EscharEx into Phase III clinical trials for venous leg ulcers, representing a potential entry into the much larger chronic wound market. Strategic partnerships have been established with major wound care companies including Solventum, Mölnlycke, MIMEDX, and Kerecis to support clinical development and future commercialization. The company secured significant non-dilutive funding, including €16.5 million from the European Innovation Council for diabetic foot ulcer development. MediWound has also diversified its revenue streams through licensing partnerships, most notably with Vericel for U.S. distribution and Kaken Pharmaceutical for Japanese markets. The company is developing specialized formulations, including a temperature-stable version for military applications in partnership with the U.S. Army.
MDWD company profile · for informational purposes only — not investment advice.
Track MDWD with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free